OPEN LABEL EXTENSION OF PROTOCOL AALS 001

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项开放标签研究的主要目的是评估已完成12周治疗和AALS-001研究第16周随访的ALS患者服用阿莫氯莫尔的长期安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this open label study is to assess the long-term safety and tolerability of arimoclomol in patients with ALS who have completed 12 weeks of treatment and the week 16 follow-up visit of the AALS-001 study.